A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: A randomized controlled trial

Prostate

Volumn 73, Issue 12, 2013, Pages 1345-1351

  Wright, Jonathan L ^a,b,c   Plymate, Stephen ^a,c   D'Oria Cameron, Andrea ^b   Bain, Carolyn ^b   Haugk, Kathy ^c   Xiao, Liren ^b   Lin, Daniel W ^a,b,c   Stanford, Janet L ^b,d   McTiernan, Anne ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

diet; obesity; prostate cancer; randomized

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; INSULIN; PROTEIN; SATURATED FATTY ACID; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; STARCH;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CALORIC RESTRICTION; CANCER EPIDEMIOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

DIET; OBESITY; PROSTATE CANCER; RANDOMIZED;

ADULT; AGED; CALORIC RESTRICTION; DIET, FAT-RESTRICTED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; PILOT PROJECTS; PROSTATIC NEOPLASMS; WEIGHT LOSS;

EID: 84881067616     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22682     Document Type: Article

References (40)

1. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF,. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109 (4): 675-684.
2. Snowdon DA, Phillips RL, Choi W,. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984; 120 (2): 244-250.
3. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ,. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10 (4): 345-353.
4. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR,. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109 (6): 1192-1202.
5. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML,. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 2006; 107 (3): 521-529.
6. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW,. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005; 174 (3): 919-922.
7. Lin DW, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, Kristal AR,. Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues. Cancer Epidemiol Biomarkers Prev 2007; 16 (10): 2150-2154.
8. Kilmer G, Roberts H, Hughes E, Li Y, Valluru B, Fan A, Giles W, Mokdad A, Jiles R,. Surveillance of certain health behaviors and conditions among states and selected local areas-Behavioral Risk Factor Surveillance System (BRFSS), United States, 2006. MMWR Surveill Summ 2008; 57 (7): 1-188.
9. Giovannucci E,. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003; 35 (11-12): 694-704.
10. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB,. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 2008; 68 (1): 11-19.
11. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M,. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99 (23): 1793-1800.
12. Hammarsten J, Hogstedt B,. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41 (18): 2887-2895.
13. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H,. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: Evidence from 96 studies. Eur J Hum Genet 2009; 17 (12): 1668-1675.
14. Firth SM, Baxter RC,. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23 (6): 824-854.
15. Rajah R, Valentinis B, Cohen P,. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272 (18): 12181-12188.
16. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P,. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007; 26 (12): 1811-1819.
17. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Durr P, Klocker H,. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 2009; 16 (3): 795-808.
18. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ,. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 2006; 147 (5): 2112-2121.
19. Parekh N, Roberts CB, Vadiveloo M, Puvananayagam T, Albu JB, Lu-Yao GL,. Lifestyle, anthropometric, and obesity-related physiologic determinants of insulin-like growth factor-1 in the Third National Health and Nutrition Examination Survey (1988-1994). Ann Epidemiol 2010; 20 (3): 182-193.
20. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, Ma J,. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010; 56 (1): 34-43.
21. Burton A, Martin RM, Holly J, Lane JA, Donovan JL, Hamdy FC, Neal DE, Tilling K,. Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: The ProtecT study. Cancer Causes Control 2013; 24 (2): 323-334.
22. Kelesidis I, Kelesidis T, Mantzoros CS,. Adiponectin and cancer: A systematic review. Br J Cancer 2006; 94 (9): 1221-1225.
23. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22 (4): 623-634.
24. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ, Look ARG,. Look AHEAD (Action for Health in Diabetes): Design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003; 24 (5): 610-628.
25. Ogden CL, Carroll MD, McDowell MA, Flegal KM,. Obesity among adults in the United States-No statistically significant chance since 2003-2004. NCHS Data Brief 2007 (1): 1-8.
26. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348 (17): 1625-1638.
27. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O,. Body size and prostate cancer: A 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89 (5): 385-389.
28. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR,. Obesity and mortality in men with locally advanced prostate cancer: Analysis of RTOG 85-31. Cancer 2007; 110 (12): 2691-2699.
29. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ,. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008; 9 (11): 1039-1047.
30. Douketis JD, Macie C, Thabane L, Williamson DF,. Systematic review of long-term weight loss studies in obese adults: Clinical significance and applicability to clinical practice. Int J Obes (2005) 2005; 29 (10): 1153-1167.
31. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research G. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393-403.
32. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR,. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174 (3): 1065-1069; discussion 9-70.
33. Li Z, Aronson WJ, Arteaga JR, Hong K, Thames G, Henning SM, Liu W, Elashoff R, Ashley JM, Heber D,. Feasibility of a low-fat/high-fiber diet intervention with soy supplementation in prostate cancer patients after prostatectomy. Eur J Clin Nutr 2008; 62 (4): 526-536.
34. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C,. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prevent Res (Philadelphia, PA) 2011; 4 (12): 2062-2071.
35. Demark-Wahnefried W, Clipp EC, Lipkus IM, Lobach D, Snyder DC, Sloane R, Peterson B, Macri JM, Rock CL, McBride CM, Kraus WE,. Main outcomes of the FRESH START trial: A sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. J Clin Oncol 2007; 25 (19): 2709-2718.
36. Parsons JK, Newman VA, Mohler JL, Pierce JP, Flatt S, Marshall J,. Dietary modification in patients with prostate cancer on active surveillance: A randomized, multicentre feasibility study. BJU Int 2008; 101 (10): 1227-1231.
37. Diabetes Prevention Program Research G, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374 (9702): 1677-1686.
38. West DS, Elaine Prewitt T, Bursac Z, Felix HC,. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, MD) 2008; 16 (6): 1413-1420.
39. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM,. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int J Cancer 2009; 124 (10): 2416-2429.
40. Rowlands MA, Holly JM, Gunnell D, Donovan JL, Athene Lane J, Hamdy F, Neal DE, Oliver S, Davey Smith G, Martin RM,. Circulating insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in PSA-detected prostate cancer: The large case control study ProtecT. Cancer Res 2012; 72 (2): 503-515.